Novel Specific Metallo-β-Lactamase Inhibitor ANT2681 Restores Meropenem Activity to Clinically Effective Levels against NDM-Positive <i>Enterobacterales</i>
Magdalena Zalacaín, Clarisse Lozano, Agustina Llanos, Nicolas Sprynski, Thomas Valmont, Cyntia De Piano, David T. Davies, Simon Leiris, Carole A. Sable, Adeline Ledoux, Ian Morrissey, Marc Lemonnier, Martin Everett
Abstract
The global dissemination of metallo-β-lactamase (MBL)-producing carbapenem-resistant Enterobacterales (CRE) is a serious public health concern. Specifically, NDM (New Delhi MBL) has been a major cause of carbapenem therapy failures in recent years, particularly as effective treatments for serine-β-lactamase (SBL)-producing Enterobacterales are now commercially available.
Topics & Concepts
MeropenemCarbapenemMedicineMicrobiologyGram-negative bacterial infectionsCarbapenem-resistant enterobacteriaceaeNew delhiEnterobacteriaceaeBiologyAntibioticsEscherichia coliAntibiotic resistanceGeneGeneticsMetropolitan areaPathologyAntibiotic Resistance in BacteriaPharmaceutical and Antibiotic Environmental ImpactsTuberculosis Research and Epidemiology